0001533743
EX-FILING FEES
0001533743
2025-09-22
2025-09-22
0001533743
1
2025-09-22
2025-09-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
Exhibit
107
Calculation
of Filing Fee Tables
Form
S-8
PROCESSA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Fees
Previously Paid
Security
Type(1) | |
Security Class Title | |
Fee Calculation Rule | |
Amount Registered (1) | | |
Proposed Maximum Offering Price Per Share(3) | | |
Maximum Aggregate Offering Price(3) | | |
Fee Rate | | |
Amount of Registration Fee | |
Equity | |
Common Stock, $0.0001 par value per share | |
Other | |
| 10,000,000 | (2) | |
$ | 0.193 | | |
$ | 1,930,000 | | |
| 0.00015310 | | |
$ | 295.48 | |
Total Offering Amounts | | |
$ | 1,930,000 | | |
| | | |
$ | 295.48 | |
Total Fee Offsets | | |
| | | |
| | | |
| - | |
Net Fee Due | | |
| | | |
| | | |
$ | 295.48 | |
|
(1) |
Pursuant
to Rule 416(a) under the Securities Act, this Registration Statement on Form S-8 (shall be deemed to cover any additional shares of the
common stock of Processa Pharmaceuticals, Inc. (the “Registrant”) that become issuable under the Amended and Restated Processa
Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan (the “Plan”) by reason of any future share splits, share dividends, recapitalizations
or any other similar transactions effected without the receipt of consideration by the Registrant, which results in an increase in the
number of outstanding shares of common stock of the Registrant. |
|
(2) |
Represents
10,000,000 additional shares of the Registrant’s common stock authorized and reserved for issuance under the Plan. |
|
(3) |
Estimated
solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act. Such computation
is based on the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Capital Market
on September 19, 2025, a date within five business days of the date of this Registration Statement. |
N/A